Search

News Focused on MS: Statistics Are Boring, But They Have Valuable Data!

What is the prevalence of multiple sclerosis? Has the proportion of patients treated with highly effective therapy changed? We bring you the latest data from around the world and domestically.

Source: Multiple Sclerosis 23. 5. 2022

News Efficacy and Safety of Fixed Combination of Olopatadine and Mometasone in Nasal Spray for Treatment of Seasonal Allergic Rhinitis

Patients with allergic rhinitis require medications with rapid onset and long duration of action. The combination of intranasal antihistamines and corticosteroids has proven effective in the past. The efficacy and safety of a fixed combination of olopatadine and mometasone in a nasal spray (GSP301) was evaluated in the study presented below by a team of American authors.

Source: Life Without Allergic Rhinitis 27. 4. 2022

News Results of ATTUNE Total Knee Replacement Implantation –⁠ Data from the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man

The ATTUNE knee replacement system was fully introduced into clinical practice in 2013. Since then, tens of thousands of implants have been administered to patients worldwide. The mid-term results are very positive, as evidenced by data from the National Joint Registry for England, Wales, Northern Ireland, and the Isle of Man.

Source: Large Joints 26. 3. 2020

News Europe and Tooth Decay: The Situation is Improving Thanks to Fluorides and New Technologies

How to prevent tooth decay? This question has been addressed by doctors for several centuries. A major breakthrough occurred in the 1960s when the effect of fluorides was discovered. However, the positive trend later stalled. Why is this and what are the other avenues in modern oral health care?

Source: Dental Caries 1. 1. 2020

News RETRO-TAS Study –⁠ Trifluridine/Tipiracil in Pretreated mCRC in Real-World Practice

How does trifluridine/tipiracil (FTD/TPI), which demonstrated efficacy in clinical trials in chemotherapy-refractory metastatic colorectal cancer (mCRC), fare in real-world practice? This was investigated by the authors of the Greek retrospective observational study RETRO-TAS.

Source: Treatment of Gastrointestinal Carcinomas 25. 5. 2023

News Direct Oral Anticoagulants and Their Reversal Agents –⁠ Current Options

In the last 10 years, the options for anticoagulant therapy have expanded with the introduction of direct oral anticoagulants (DOACs). It appears that DOACs may soon replace warfarin in the first line of prevention of venous thromboembolism, not only due to their clinical advantages but also thanks to newly available reversal agents that can be administered in case of major bleeding in patients taking DOACs. A recently published review article summarizes the current situation in this area.

Source: Anticoagulant Treatment 19. 11. 2020

News Bimekizumab –⁠ Higher Chance of Complete Skin Healing in Moderate to Severe Psoriasis?

In August 2021, the European Medicines Agency (EMA) approved bimekizumab (Bimzelx LP) as the first psoriasis treatment that selectively and directly inhibits interleukins IL-17A and IL-17F. It is intended for the treatment of moderate to severe plaque psoriasis in adults for whom systemic treatment is appropriate. The approval is based on three Phase III clinical studies in which bimekizumab demonstrated a very high rate of skin healing compared to placebo and active treatments like ustekinumab and adalimumab, as well as good tolerability.

Source: Psoriasis 12. 4. 2022

News Effect of Denosumab and Zoledronic Acid on Overall Survival in Patients with Metastatic Lung Cancer

In 30-40% of patients with non-small cell lung cancer (NSCLC), bone metastases develop during the course of the disease, causing so-called skeletal-related events (SREs). These events cause pain, increase morbidity, and reduce quality of life and mobility in patients. Antiresorptive agents, such as the bisphosphonate zoledronic acid or the osteoclast maturation and differentiation inhibitor denosumab, are used to prevent the occurrence of SREs. An exploratory analysis compared the effect of administering denosumab and zoledronic acid on the survival of patients with metastatic disease.

Source: Prevention of Bone Events 12. 9. 2022

News Morning Myopic Shift and Glare in Patients with Advanced Fuchs Endothelial Corneal Dystrophy

A newly published study by a German team analyzes the morning and afternoon differences in various parameters in patients with Fuchs endothelial corneal dystrophy to determine which of them contribute to subjective visual difficulties in the morning.

Source: Glaucoma 8. 6. 2020

News Dust mite allergy is a significant risk factor (not only) for the development of asthma

Dust mite allergy is the most common cause of year-round allergic rhinitis in our country. Its prevalence is increasing every year, but non-specific manifestations also cause its underdiagnosis. Early initiation of treatment is crucial to prevent the development of complications.

Source: Dust Mite Allergy 14. 3. 2022

News Scientists Create First Functional Brain Tissue Using 3D Printing

A research team from the University of Wisconsin-Madison has successfully printed the first ever functional brain tissue using a commercial 3D printer in their laboratory. This breakthrough may be beneficial not only for scientists studying the pathogenesis of neurological and neurodevelopmental diseases but could even mark the beginning of a journey towards a deeper understanding of how neurons function, how brain development occurred, and how different parts of the brain communicate with each other.

Source: 9. 4. 2024

News Augmentation Therapy of Bronchiectasis Due to AATD –⁠ Case Report

Alpha-1-antitrypsin deficiency (AATD) is a rare cause of bronchiectasis unrelated to cystic fibrosis. The role of augmentation therapy with alpha-1-antitrypsin (AAT) in patients with AATD with bronchiectasis without pulmonary emphysema is still unclear. A case report from authors in Heidelberg presents a patient with bronchiectasis based on AATD, where augmentation therapy reduced the number of exacerbations and improved clinical condition.

Source: Deficiency of Alpha-1-Antitrypsin 26. 4. 2023

News Weight-Based Enoxaparin Dosing vs. Standard Dosing in Trauma Patients

Thromboembolic disease is a common comorbidity in adult trauma patients, thus making routine thromboprophylaxis appropriate for these patients, most often in the form of low-molecular-weight heparins (LMWH). Standard thromboprophylaxis dosing regimens, however, are often associated with insufficient anti-Xa activity levels. A recently published clinical study by researchers from New York University focused on comparing the standard thromboprophylaxis regimen of enoxaparin with a weight-based dosing regimen in adult trauma patients.

Source: Thromboprophylaxis 9. 3. 2022

News Distribution and Localization of Specifically Modified Exosomes Can Improve the Treatment of Muscular Dystrophies

A research team from several Milanese universities, in a study published in Nature Nanotechnology, focused on developing a new method for muscular dystrophy therapy. Specifically modified exosomes were enriched with the protein annexin A1 and delivered into dystrophic muscle cells using ferromagnetic nanotubes guided by an external magnetic field. This triggered healing processes in damaged cells and tissues in a mouse model.

Source: 3. 12. 2024

News Physiotherapy as Part of Comprehensive Care for People with Hemophilia –⁠ Recommendations vs. Reality

It appears that the physiotherapeutic care provided in reality to people with hemophilia does not align with current recommendations, which see it as an integral part of a multidisciplinary approach. Therefore, in the summer of 2020, an initiative of experts from various countries, including the Czech Republic, was formed to address this issue.

Source: Hemophilia with Movement 30. 11. 2020